Ipratropium Bromide (Page 2 of 2)
OVERDOSAGE
Acute systemic overdosage by inhalation is unlikely since ipratropium bromide is not well absorbed after inhalation at up to four-fold the recommended dose, or after oral administration at up to forty-fold the recommended dose. The oral LD50 of ipratropium bromide ranged between 1,001 and 2,010 mg/kg in mice; between 1,667 and 4,000 mg/kg in rats; and between 400 and 1,300 mg/kg in dogs.
DOSAGE AND ADMINISTRATION
The usual dosage of Ipratropium Bromide Inhalation Solution is 500 mcg (1 Unit-Dose Vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium Bromide Inhalation Solution Unit-Dose Vials contain 500 mcg ipratropium bromide, USP anhydrous in 2.5 mL normal saline. Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established.
HOW SUPPLIED
Ipratropium Bromide Inhalation Solution, USP is a clear, colorless solution supplied in a unit-dose vial containing 2.5 mL. Supplied in cartons as listed below:
NDC 47335-706-49 carton of 25 vials (5 vials per foil pouch)
NDC 47335-706-52 carton of 30 vials (5 vials per foil pouch)
NDC 47335-706-54 carton of 60 vials (5 vials per foil pouch)
Each vial is made from a low density polyethylene (LDPE) resin.
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light. Store in pouch until time of use.
Dispense with Patient’s Instructions For Use available at: https://www.sunpharma.com/usa/products
Patient’s Instructions for Use
Ipratropium Bromide (IH-pruh-TROE-pee-uhm BROE-mide)
Inhalation Solution, USP 0.02%
Read complete instructions carefully before using.
1. Remove vial from the foil pouch.
2. Twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir (Figure 1).
3. Connect the nebulizer reservoir to the mouthpiece or face mask (Figure 2).
4. Connect the nebulizer to the compressor.
5. Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or put on the face mask and turn on the compressor. If a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of vision, pupil enlargement, precipitation or worsening of narrow-angle glaucoma, or eye pain may occur if the solution comes into direct contact with the eyes.
6. Breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). At this point, the treatment is finished.
7. Clean the nebulizer (see manufacturer’s instructions).
Note: Use only as directed by your physician. More frequent administration or higher doses are not recommended. Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established.
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light. Store in pouch until time of use.
ADDITIONAL INSTRUCTIONS: __________________________________________
Dispense with Patient’s Instructions For Use available at: https://www.sunpharma.com/usa/products
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Manufactured by:
Sun Pharmaceutical Medicare Limited
Baska Ujeti Road, Ujeti
Halol-389350, Gujarat, India
5230899
ISS. 4/2022
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-706-54
Ipratropium Bromide Inhalation Solution, USP
0.02% (0.5 mg/2.5 mL)
For Oral Inhalation Only
Rx only
60 X 2.5 mL Sterile Unit-Dose Vials
(5 Unit-Dose Vials per pouch, 12 pouches per carton)
PHARMACIST: Dispense with “Patient’s Instructions For Use” to each patient.
SUN PHARMA
IPRATROPIUM BROMIDE ipratropium bromide solution | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
|
Labeler — Sun Pharmaceutical Industries, Inc. (146974886) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Sun Pharmaceutical Medicare Limited | 725420835 | ANALYSIS (47335-706), MANUFACTURE (47335-706) |
Revised: 04/2022 Sun Pharmaceutical Industries, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/ipratropium-bromide-19/page/2/